This phase II study is evaluating how effective targeted therapy (darovasertib) is people with occular (uveal) melanoma who are planned to undergo surgery.
This trial is treating patients with occular melanoma (uveal).
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
Other Non-Commercial Sponsor
Anthony Joshua, FRACP
Eligible participants will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a day as a starting dose) after fulfilling inclusion/exclusion criteria and consent. Select participants will undergo adjuvant treatment for 6 months based on their initial response.
Recruiting Hospitals Read More